Phase 2 DUET Study Published in the Journal of the American Society of Nephrology
Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
FILSPARI (sparsentan) – Safety Data Sheet
FILSPARI (sparsentan) – Effect on Proteinuria in Focal Segmental Glomerulosclerosis
FILSPARI (sparsentan) – Pediatric Patients in Sparsentan FSGS Studies
FILSPARI (sparsentan) – Baseline Characteristics of Asian vs Non-Asian Patients in the PROTECT Study
Sparsentan in Patients With IgA Nephropathy: A Prespecified Interim Analysis From a Randomised, Double-Blind, Active-Controlled Clinical Trial
FILSPARI (sparsentan) – Hyperkalemia
Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug–Drug Interaction Study in Healthy Adults
FILSPARI (sparsentan) – Acute Kidney Injury
FILSPARI (sparsentan) – Impact on Pregnancy, Lactation, and Fertility
FILSPARI (sparsentan) – DUPLEX (Phase 3 Study): Study Design & Topline Results
FILSPARI (sparsentan) Dual Receptor Antagonism in Renal Pathophysiology and Reduction of Proteinuria